Continued reduction in HPV prevalence and early evidence of herd immunity following the human papillomavirus vaccination programme in Scotland

Ross L Cameron, Kimberley Kavanagh, Jiafeng Pan, John Love, Kate Cuschieri, Chris Robertson, Syed Ahmed, Timothy Palmer, Kevin G.J. Pollock

Research output: Contribution to journalArticle

63 Citations (Scopus)

Abstract

In 2008, a national human papillomavirus (HPV) immunization program using a bivalent vaccine against HPV types 16 and 18 was implemented in Scotland along with a national surveillance program designed to determine the longitudinal effects of vaccination on HPV infection at the population level. Each year during 2009–2013, the surveillance program conducted HPV testing on a proportion of liquid-based cytology samples from women undergoing their first cervical screening test for precancerous cervical disease. By linking vaccination, cervical screening, and HPV testing data, over the study period we found a decline in HPV types 16 and 18, significant decreases in HPV types 31, 33, and 45 (suggesting cross-protection), and a nonsignificant increase in HPV 51. In addition, among nonvaccinated women, HPV types 16 and 18 infections were significantly lower in 2013 than in 2009. Our results preliminarily indicate herd immunity and sustained effectiveness of the bivalent vaccine on virologic outcomes at the population level.
LanguageEnglish
Pages56-64
Number of pages9
JournalEmerging Infectious Diseases
Volume22
Issue number1
DOIs
Publication statusPublished - 1 Jan 2016

Fingerprint

Herd Immunity
Vaccination
Scotland
Immunity
Human papillomavirus 18
Human papillomavirus 16
Human papillomavirus 31
Vaccines
Cross Protection
Vaccine
Immunization Programs
Papillomavirus Infections
Surveillance
Screening
Infection
Population
Cell Biology
Evidence
Human
Immunization

Keywords

  • human papillomavirus vaccine
  • cancer screening
  • prevalence
  • cervical cancer
  • herd immunity

Cite this

@article{99e2ac6a5cb94b9fa58aae9f9d6d4608,
title = "Continued reduction in HPV prevalence and early evidence of herd immunity following the human papillomavirus vaccination programme in Scotland",
abstract = "In 2008, a national human papillomavirus (HPV) immunization program using a bivalent vaccine against HPV types 16 and 18 was implemented in Scotland along with a national surveillance program designed to determine the longitudinal effects of vaccination on HPV infection at the population level. Each year during 2009–2013, the surveillance program conducted HPV testing on a proportion of liquid-based cytology samples from women undergoing their first cervical screening test for precancerous cervical disease. By linking vaccination, cervical screening, and HPV testing data, over the study period we found a decline in HPV types 16 and 18, significant decreases in HPV types 31, 33, and 45 (suggesting cross-protection), and a nonsignificant increase in HPV 51. In addition, among nonvaccinated women, HPV types 16 and 18 infections were significantly lower in 2013 than in 2009. Our results preliminarily indicate herd immunity and sustained effectiveness of the bivalent vaccine on virologic outcomes at the population level.",
keywords = "human papillomavirus vaccine, cancer screening, prevalence, cervical cancer, herd immunity",
author = "Cameron, {Ross L} and Kimberley Kavanagh and Jiafeng Pan and John Love and Kate Cuschieri and Chris Robertson and Syed Ahmed and Timothy Palmer and Pollock, {Kevin G.J.}",
year = "2016",
month = "1",
day = "1",
doi = "10.3201/eid2201.150736",
language = "English",
volume = "22",
pages = "56--64",
journal = "Emerging Infectious Diseases",
issn = "1080-6059",
number = "1",

}

Continued reduction in HPV prevalence and early evidence of herd immunity following the human papillomavirus vaccination programme in Scotland. / Cameron, Ross L; Kavanagh, Kimberley; Pan, Jiafeng; Love, John; Cuschieri, Kate; Robertson, Chris; Ahmed, Syed; Palmer, Timothy; Pollock, Kevin G.J.

In: Emerging Infectious Diseases, Vol. 22, No. 1, 01.01.2016, p. 56-64.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Continued reduction in HPV prevalence and early evidence of herd immunity following the human papillomavirus vaccination programme in Scotland

AU - Cameron, Ross L

AU - Kavanagh, Kimberley

AU - Pan, Jiafeng

AU - Love, John

AU - Cuschieri, Kate

AU - Robertson, Chris

AU - Ahmed, Syed

AU - Palmer, Timothy

AU - Pollock, Kevin G.J.

PY - 2016/1/1

Y1 - 2016/1/1

N2 - In 2008, a national human papillomavirus (HPV) immunization program using a bivalent vaccine against HPV types 16 and 18 was implemented in Scotland along with a national surveillance program designed to determine the longitudinal effects of vaccination on HPV infection at the population level. Each year during 2009–2013, the surveillance program conducted HPV testing on a proportion of liquid-based cytology samples from women undergoing their first cervical screening test for precancerous cervical disease. By linking vaccination, cervical screening, and HPV testing data, over the study period we found a decline in HPV types 16 and 18, significant decreases in HPV types 31, 33, and 45 (suggesting cross-protection), and a nonsignificant increase in HPV 51. In addition, among nonvaccinated women, HPV types 16 and 18 infections were significantly lower in 2013 than in 2009. Our results preliminarily indicate herd immunity and sustained effectiveness of the bivalent vaccine on virologic outcomes at the population level.

AB - In 2008, a national human papillomavirus (HPV) immunization program using a bivalent vaccine against HPV types 16 and 18 was implemented in Scotland along with a national surveillance program designed to determine the longitudinal effects of vaccination on HPV infection at the population level. Each year during 2009–2013, the surveillance program conducted HPV testing on a proportion of liquid-based cytology samples from women undergoing their first cervical screening test for precancerous cervical disease. By linking vaccination, cervical screening, and HPV testing data, over the study period we found a decline in HPV types 16 and 18, significant decreases in HPV types 31, 33, and 45 (suggesting cross-protection), and a nonsignificant increase in HPV 51. In addition, among nonvaccinated women, HPV types 16 and 18 infections were significantly lower in 2013 than in 2009. Our results preliminarily indicate herd immunity and sustained effectiveness of the bivalent vaccine on virologic outcomes at the population level.

KW - human papillomavirus vaccine

KW - cancer screening

KW - prevalence

KW - cervical cancer

KW - herd immunity

U2 - 10.3201/eid2201.150736

DO - 10.3201/eid2201.150736

M3 - Article

VL - 22

SP - 56

EP - 64

JO - Emerging Infectious Diseases

T2 - Emerging Infectious Diseases

JF - Emerging Infectious Diseases

SN - 1080-6059

IS - 1

ER -